PMID- 26394669
OWN - NLM
STAT- MEDLINE
DCOM- 20161006
LR  - 20181113
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Print)
IS  - 1058-4838 (Linking)
VI  - 62
IP  - 2
DP  - 2016 Jan 15
TI  - A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three 
      Cases of Mycobacterial IRIS.
PG  - 258-261
LID - 10.1093/cid/civ841 [doi]
AB  - The management of corticosteroid refractory immune reconstitution inflammatory 
      syndrome (IRIS) is currently unclear. Infliximab administration was associated 
      with clinical improvement without significant adverse events in 3 patients with 
      mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy 
      were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and 
      warrants further study in clinical trials.
CI  - Published by Oxford University Press for the Infectious Diseases Society of 
      America 2015. This work is written by (a) US Government employee(s) and is in the 
      public domain in the US.
FAU - Hsu, Denise C
AU  - Hsu DC
AD  - National Institute of Allergy and Infectious Diseases (NIAID), National 
      Institutes of Health (NIH), Bethesda, Maryland.
FAU - Faldetta, Kimberly F
AU  - Faldetta KF
AD  - National Institute of Allergy and Infectious Diseases (NIAID), National 
      Institutes of Health (NIH), Bethesda, Maryland.
FAU - Pei, Luxin
AU  - Pei L
AD  - National Institute of Allergy and Infectious Diseases (NIAID), National 
      Institutes of Health (NIH), Bethesda, Maryland.
FAU - Sheikh, Virginia
AU  - Sheikh V
AD  - National Institute of Allergy and Infectious Diseases (NIAID), National 
      Institutes of Health (NIH), Bethesda, Maryland.
FAU - Utay, Netanya S
AU  - Utay NS
AD  - Department of Internal Medicine, Division of Infectious Diseases, University of 
      Texas Medical Branch, Galveston.
FAU - Roby, Gregg
AU  - Roby G
AD  - National Institute of Allergy and Infectious Diseases (NIAID), National 
      Institutes of Health (NIH), Bethesda, Maryland.
FAU - Rupert, Adam
AU  - Rupert A
AD  - Leidos Biomedical Research, Inc, Frederick, Maryland.
FAU - Fauci, Anthony S
AU  - Fauci AS
AD  - National Institute of Allergy and Infectious Diseases (NIAID), National 
      Institutes of Health (NIH), Bethesda, Maryland.
FAU - Sereti, Irini
AU  - Sereti I
AD  - National Institute of Allergy and Infectious Diseases (NIAID), National 
      Institutes of Health (NIH), Bethesda, Maryland.
LA  - eng
GR  - HHSN261200800001C/RC/CCR NIH HHS/United States
GR  - HHSN261200800001E/CA/NCI NIH HHS/United States
GR  - 261200800001E/PHS HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150922
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (Immunologic Factors)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adult
MH  - Anti-Retroviral Agents/adverse effects/therapeutic use
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - HIV Infections/drug therapy
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/*drug therapy
MH  - Immunologic Factors/*therapeutic use
MH  - Infliximab/adverse effects/*therapeutic use
MH  - Male
MH  - Treatment Outcome
MH  - Tuberculosis/*drug therapy
PMC - PMC4690485
OTO - NOTNLM
OT  - immune reconstitution inflammatory syndrome
OT  - infliximab
OT  - mycobacterial infection
EDAT- 2015/09/24 06:00
MHDA- 2016/10/08 06:00
PMCR- 2017/01/15
CRDT- 2015/09/24 06:00
PHST- 2015/08/06 00:00 [received]
PHST- 2015/09/10 00:00 [accepted]
PHST- 2015/09/24 06:00 [entrez]
PHST- 2015/09/24 06:00 [pubmed]
PHST- 2016/10/08 06:00 [medline]
PHST- 2017/01/15 00:00 [pmc-release]
AID - civ841 [pii]
AID - 10.1093/cid/civ841 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2016 Jan 15;62(2):258-261. doi: 10.1093/cid/civ841. Epub 2015 
      Sep 22.